Diagnosis and treatment development and innovations of glioma in China 2024

Abstract

In 2024, significant advancements were made in the diagnosis, treatment, and research of glioma in China, reflecting a comprehensive innovation in basic research, diagnostic technologies, surgical techniques, targeted therapies, immunotherapies, and integrated management. This development showcases China's increasing capabilities in translating basic research into clinical applications, advancing the precision and intelligence of glioma care. Key achievements include the major academic organizations had played pivotal roles in glioma research and clinical practice. Notably, the establishment of the Glioma MDT Specialist Alliance under the National Center for Neurological Disorders had enhanced resource integration, promoted multidisciplinary collaboration, and accelerated knowledge sharing and clinical translation. The approval of mesenchymal⁃epithelial transition (MET) inhibitors for glioma harboring the PTPRZ1⁃MET fusion gene marked a milestone in precision oncology. Artificial intelligence (AI) has been widely adopted in glioma research. Breakthroughs in rapid intraoperative molecular diagnostics, combined with AI⁃powered imaging analysis and clustered regularly interspaced short palindromic repeats (CRISPR), were poised to revolutionize precision diagnosis and treatment. These developments underscore China's growing leadership in integrating cutting⁃edge technologies to address complex challenges in neuro⁃oncology.

doi：10.3969/j.issn.1672⁃6731.2025.03.001